but it's also nice to see the ESMO develop the way, it has developed in the last few years and show so much good data. This is our forward-looking statement. This is the agenda. I'll say a few ...

Vecima Networks Inc. today announced the retirement of CFO Dale Booth following a distinguished 42-year professional career, including 13 years with Vecima. "I want to express my deep appreciation to ...

Labcorp , a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. , a multinational biopharmaceutical and diagnostics company, announced today the completion of ...

Vice President Kamala Harris unveiled her economic agenda at a rally on Friday ... on – are an invaluable asset. The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended ...

Join over 80 attendees and 24 speaking experts and learn how to: Click here to view the full agenda and speaker ... invaluable asset. The European Society for Medical Oncology (ESMO) 2024 meeting ...

Using Herceptin as an example, Andre Ilbawi detailed the challenges low- and medium-income countries face in accessing essential therapies.

The latest data cut, which Jazz presented at the European Society for Medical Oncology conference in Barcelon, Spain on Monday morning, follows the release of 18-month data from the same phase 2 ...

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner to get a termination notice, leaving it in full control of a ...

Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European Society for Medical Oncology (ESMO) 2024 Congress were the 10-year data from the ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...